HCM
BIB icon

Howard Capital Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Howard Capital Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-209,901
Closed -$19.9M – 75
2021
Q3 		$19.9M Buy
+209,901
New +$21.2M 2.95% 7
2018
Q4 		– Sell
-100,000
Closed -$6.93M – 19
2018
Q3 		$6.93M Buy
+100,000
New +$6.54M 0.67% 64

Other funds holding BIB

OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Howard Capital Management's BIB Position: Q4 2021 in Review

Howard Capital Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2021, closing a stake of 209,901 shares — an estimated $19.9M sold.

Howard Capital Management first reported a position in BIB in Q3 2018 and held it in 2 quarters. The position peaked at $19.9M in Q3 2021. 37 funds tracked by Wall St. Rank hold BIB as of Q4 2021.

  • Howard Capital Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Howard Capital Management sold 209,901 ProShares Ultra NASDAQ Biotechnology shares in Q4 2021, an estimated $19.9M.
  • Howard Capital Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2018 and held it in 2 quarters.
  • Howard Capital Management's ProShares Ultra NASDAQ Biotechnology position peaked at $19.9M in Q3 2021.
  • 37 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2021.

Based on Howard Capital Management's 13F filing for Q4 2021, filed 31 Jan 2022.